About Us
Saronic Biotechnology, Inc. is committed to developing novel immunotherapies to cure liver cancer.
Our Story
A New York City-based company founded by physicians and research scientists with broad expertise in oncology, viral hepatitis, and immunology, Saronic Biotechnology has developed a highly promising cellular immunotherapy for hepatocellular carcinoma (HCC). HCC is the most common primary liver cancer and the third leading cause of cancer-related mortality worldwide 1,2
SBI1997
Saronic Biotechnology developed SBI1997, a highly promising cellular immunotherapy for patients with HCC. SBI1997 showed unprecedented results in a preclinical model, and has the potential to decrease likelihood of cancer recurrence, shrink existing tumors, and extend life for patients diagnosed with HCC.
1 de Lope CR et al. Management of HCC. J Hepatol. 2012; 56 Suppl 1: S75-87.
2 Arzumanyan A et al. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. February 2013; 13 (2): 123-35.
